Sentinel Diagnostics Launches Two New Serological Tests to Quickly Assess Immunoresponse to SARS-CoV-2

Sentinel Diagnostics (Milan, Italy) has launched two new serological tests for the detection of total antibodies (IgA, IgG and IgM) to SARS-CoV-2 specific proteins in human serum that will help to quickly assess the immune response to the novel coronavirus of patients and entire communities.

The application of Sentinel’s new serological tests, COVID-19 Anti-S1 Total Ab and COVID-19 Anti-NC Total Ab, would help to identify those individuals who have correctly developed antibodies after infection and/or vaccination, supporting the understanding of the degree of diffusion of COVID-19 in the community and the results of the efforts made by countries for vaccination campaigns.

Both COVID-19 Anti-S1 Total Ab and COVID-19 Anti-NC Total Ab assays are In Vitro Diagnostic tests, for quantitative and qualitative analysis with immunoturbimetric method, designed to process hundreds of results in one hour and thousands in a single day when used on the company’s Sentinel SENTIFIT 270 Analyzer or other automated analytical platforms. More...